Crescent Biopharma, Inc. (CBIO)
NASDAQ: CBIO · Real-Time Price · USD
17.69
-0.52 (-2.86%)
Jun 18, 2026, 4:00 PM EDT - Market closed
Crescent Biopharma Revenue
Crescent Biopharma had revenue of $1.04M in the quarter ending March 31, 2026. This brings the company's revenue in the last twelve months to $11.88M. In the year 2025, Crescent Biopharma had annual revenue of $10.84M.
Revenue (ttm)
$11.88M
Revenue Growth
n/a
P/S Ratio
49.47
Revenue / Employee
$216,055
Employees
55
Market Cap
587.82M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 10.84M | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | 10.00K | -65.00K | -86.67% |
| Dec 31, 2022 | 75.00K | -1.08M | -93.53% |
| Dec 31, 2021 | 1.16M | -9.00M | -88.59% |
| Dec 31, 2020 | 10.16M | - | - |
| Dec 31, 2019 | - | - | - |
| Dec 31, 2018 | - | - | - |
| Dec 31, 2017 | - | - | - |
| Dec 31, 2016 | 18.50M | -1.57M | -7.83% |
| Dec 31, 2015 | 20.07M | 5.04M | 33.56% |
| Dec 31, 2014 | 15.03M | 11.03M | 276.37% |
| Dec 31, 2013 | 3.99M | -11.26M | -73.83% |
| Dec 31, 2012 | 15.26M | 11.44M | 300.05% |
| Dec 31, 2011 | 3.81M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionCBIO News
- 8 days ago - Crescent Biopharma Announces Grants of Inducement Awards - GlobeNewsWire
- 11 days ago - Crescent Biopharma Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026 - Transcripts
- 16 days ago - Crescent Biopharma Transcript: Jefferies Global Healthcare Conference 2026 - Transcripts
- 17 days ago - Crescent Biopharma to Present at June Investor Conferences - GlobeNewsWire
- 17 days ago - Crescent Biopharma Transcript: AGM 2026 - Transcripts
- 18 days ago - Crescent Biopharma downgraded to Neutral from Buy at H.C. Wainwright - TheFly
- 24 days ago - Crescent Biopharma Transcript: 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA - Transcripts
- 4 weeks ago - Crescent Biopharma Announces Trial in Progress Presentation for ASCEND Study of CR-001, a PD-1 x VEGF Bispecific Antibody, at Upcoming American Society of Clinical Oncology (ASCO) 2026 Annual Meeting - GlobeNewsWire